PURPOSE: Breast Cancer is one of the leading causes of cancer deaths among women worldwide. The role of epigenetics as a distinct mechanism to alter gene expression in a tissue-specific manner has emerged as an important mechanism in the pathophysiology of cancer. Present study was carried out to assess the role of methylation in regulating transcription and protein expression of Insulin-like growth factor 2 (IGF2), an oncogene with parental imprinting. METHODS: Paraffin-embedded archival breast tumor and adjacent normal tissue samples were used for carrying out PCR-based methylation assay, genomic PCR, immunohistochemistry and Real-Time Reverse transcriptase PCR. RESULTS: A significant loss of methylation in exon 9 CpG cluster of IGF2 in breast tumor tissues was observed when compared to normal tissue (P < 0.0001). Expression of IGF2 by immunohistochemistry exhibited a mean twofold increase correlating with the hypomethylation of this specific CpG. Real-Time RT PCR showed increased transcripts in the tumor tissue supporting the IHC and methylation results. A total of 33% of tumor samples heterozygous for the ApaI IGF2 polymorphism exhibited biallelic IGF2 expression due to loss of imprinting; this was not seen in any of the normal breast tissues. CONCLUSIONS: Altered methylation of exonic CpG plays an important role in the enhanced transcription/expression of IGF2 in breast tumors. Methylation analysis of exon 9 CpG can be used as a biomarker for upregulation of IGF2 in breast tumor tissue and maybe developed as a diagnostic test in future.
PURPOSE:Breast Cancer is one of the leading causes of cancer deaths among women worldwide. The role of epigenetics as a distinct mechanism to alter gene expression in a tissue-specific manner has emerged as an important mechanism in the pathophysiology of cancer. Present study was carried out to assess the role of methylation in regulating transcription and protein expression of Insulin-like growth factor 2 (IGF2), an oncogene with parental imprinting. METHODS:Paraffin-embedded archival breast tumor and adjacent normal tissue samples were used for carrying out PCR-based methylation assay, genomic PCR, immunohistochemistry and Real-Time Reverse transcriptase PCR. RESULTS: A significant loss of methylation in exon 9 CpG cluster of IGF2 in breast tumor tissues was observed when compared to normal tissue (P < 0.0001). Expression of IGF2 by immunohistochemistry exhibited a mean twofold increase correlating with the hypomethylation of this specific CpG. Real-Time RT PCR showed increased transcripts in the tumor tissue supporting the IHC and methylation results. A total of 33% of tumor samples heterozygous for the ApaI IGF2 polymorphism exhibited biallelic IGF2 expression due to loss of imprinting; this was not seen in any of the normal breast tissues. CONCLUSIONS: Altered methylation of exonic CpG plays an important role in the enhanced transcription/expression of IGF2 in breast tumors. Methylation analysis of exon 9 CpG can be used as a biomarker for upregulation of IGF2 in breast tumor tissue and maybe developed as a diagnostic test in future.
Authors: P S H Soon; A J Gill; D E Benn; A Clarkson; B G Robinson; K L McDonald; S B Sidhu Journal: Endocr Relat Cancer Date: 2009-02-13 Impact factor: 5.678
Authors: C E van Roozendaal; A J Gillis; J G Klijn; B van Ooijen; C J Claassen; A M Eggermont; S C Henzen-Logmans; J W Oosterhuis; J A Foekens; L H Looijenga Journal: FEBS Lett Date: 1998-10-16 Impact factor: 4.124
Authors: Lingeng Lu; Dionyssios Katsaros; Andrew Wiley; Irene A Rigault de la Longrais; Harvey A Risch; Manuela Puopolo; Herbert Yu Journal: Clin Cancer Res Date: 2006-02-15 Impact factor: 12.531
Authors: S D Merajver; T M Pham; R F Caduff; M Chen; E L Poy; K A Cooney; B L Weber; F S Collins; C Johnston; T S Frank Journal: Nat Genet Date: 1995-04 Impact factor: 38.330
Authors: Yoko Ito; Thibaud Koessler; Ashraf E K Ibrahim; Sushma Rai; Sarah L Vowler; Sayeda Abu-Amero; Ana-Luisa Silva; Ana-Teresa Maia; Joanna E Huddleston; Santiago Uribe-Lewis; Kathryn Woodfine; Maja Jagodic; Raffaella Nativio; Alison Dunning; Gudrun Moore; Elena Klenova; Sheila Bingham; Paul D P Pharoah; James D Brenton; Stephan Beck; Manjinder S Sandhu; Adele Murrell Journal: Hum Mol Genet Date: 2008-06-09 Impact factor: 6.150
Authors: Timothy M Barrow; Ludovic Barault; Rachel E Ellsworth; Holly R Harris; Alexandra M Binder; Allyson L Valente; Craig D Shriver; Karin B Michels Journal: Int J Cancer Date: 2015-01-21 Impact factor: 7.396
Authors: Susan K Murphy; Abayomi Adigun; Zhiqing Huang; Francine Overcash; Frances Wang; Randy L Jirtle; Joellen M Schildkraut; Amy P Murtha; Edwin S Iversen; Cathrine Hoyo Journal: Gene Date: 2011-12-20 Impact factor: 3.688
Authors: Mattia Lion; Alessandra Bisio; Toma Tebaldi; Veronica De Sanctis; Daniel Menendez; Michael A Resnick; Yari Ciribilli; Alberto Inga Journal: Cell Cycle Date: 2013-03-21 Impact factor: 4.534
Authors: Cathrine Hoyo; Kimberly Fortner; Amy P Murtha; Joellen M Schildkraut; Adelheid Soubry; Wendy Demark-Wahnefried; Randy L Jirtle; Joanne Kurtzberg; Michele R Forman; Francine Overcash; Zhiqing Huang; Susan K Murphy Journal: Cancer Causes Control Date: 2012-03-06 Impact factor: 2.506
Authors: Ludovic Barault; Rachel E Ellsworth; Holly R Harris; Allyson L Valente; Craig D Shriver; Karin B Michels Journal: PLoS One Date: 2013-02-07 Impact factor: 3.240